Tema Etfs LLC Acquires Shares of 34,788 Schrödinger, Inc. (NASDAQ:SDGR)

Tema Etfs LLC bought a new stake in Schrödinger, Inc. (NASDAQ:SDGR) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 34,788 shares of the company’s stock, valued at approximately $671,000.

Other hedge funds also recently modified their holdings of the company. Point72 Hong Kong Ltd bought a new position in shares of Schrödinger in the 4th quarter valued at about $27,000. Paradigm Asset Management Co. LLC bought a new position in shares of Schrödinger in the 4th quarter valued at about $50,000. KBC Group NV boosted its stake in Schrödinger by 73.9% during the 4th quarter. KBC Group NV now owns 4,361 shares of the company’s stock worth $84,000 after acquiring an additional 1,853 shares during the last quarter. XTX Topco Ltd bought a new position in Schrödinger during the 4th quarter worth approximately $199,000. Finally, Bayesian Capital Management LP bought a new position in Schrödinger during the 4th quarter worth approximately $199,000. Institutional investors own 79.05% of the company’s stock.

Schrödinger Stock Performance

Shares of SDGR stock opened at $23.58 on Friday. The company has a market capitalization of $1.72 billion, a P/E ratio of -10.08 and a beta of 1.84. The company’s 50 day moving average price is $22.89 and its two-hundred day moving average price is $21.99. Schrödinger, Inc. has a 52 week low of $16.60 and a 52 week high of $28.47.

Schrödinger (NASDAQ:SDGR) last announced its earnings results on Wednesday, May 7th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.01). The company had revenue of $59.55 million for the quarter, compared to analyst estimates of $54.60 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The business’s quarterly revenue was up 62.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.86) earnings per share. Analysts forecast that Schrödinger, Inc. will post -2.37 earnings per share for the current year.

Insiders Place Their Bets

In other news, CFO Geoffrey Craig Porges sold 5,491 shares of Schrödinger stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total value of $119,484.16. Following the sale, the chief financial officer now directly owns 27,544 shares in the company, valued at $599,357.44. This trade represents a 16.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Karen Akinsanya sold 16,723 shares of Schrödinger stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $25.09, for a total transaction of $419,580.07. Following the completion of the sale, the insider now owns 15,625 shares in the company, valued at $392,031.25. This trade represents a 51.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Piper Sandler reduced their price objective on shares of Schrödinger from $50.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. KeyCorp lifted their price objective on shares of Schrödinger from $30.00 to $32.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. One analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Schrödinger currently has an average rating of “Buy” and a consensus target price of $32.80.

Schrödinger Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.